

Patient ID SA00161409	Patient Name TESTINGRNV, ADALP N	Birth Date 1980-09-09	Sex M	Age 42
Order Number SA00161409	Client Order Number SA00161409	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 31 Jul 2023 00:00		

Adalimumab QN with Antibodies, S

Adalimumab Interpretation

SDL

At this concentration of adalimumab (ADL), a low (50–150 AU/mL) or moderate titer (150–500 AU/mL) ATA cannot be excluded. The presence of a high-titer ATA (≥ 500 U/mL) is unlikely, but also cannot be completely excluded.

If there is clinical suspicion for an ATA, suggest submission of a new sample obtained at trough, preferably during the maintenance phase of therapy.

This test has demonstrated drug tolerance up to 40 mcg/mL for ATAs ≥ 500 AU/mL, up to 15 mcg/mL for ATAs between 150–500 and up to 8 mcg/mL ADL for ATAs between 50–150 AU/mL.

Adalimumab QN, S

1 SDL

35.0 mcg/mL

REFERENCE VALUE

Limit of Quantitation = 0.8 mcg/mL

Adalimumab Ab, S

1 SDL

<10.0 AU/mL
Reference Value
 <14.0

Received: 01 Aug 2023 09:05

Reported: 01 Aug 2023 09:57

Laboratory Notes

- 1 This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592